Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice by Bassi, Elena et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 897076, 8 pages
doi:10.1155/2012/897076
Research Article
Persistent Dystrophin Protein Restoration 90 Days after
a Course of Intraperitoneally Administered Naked
2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice
Elena Bassi,1 Sofia Falzarano,1 Marina Fabris,1 Francesca Gualandi,1
Luciano Merlini,2 Gaetano Vattemi,3 Daniela Perrone,4 Elena Marchesi,4
Patrizia Sabatelli,5 Katia Sparnacci,6 Michele Laus,6 Paolo Bonaldo,7
Paola Rimessi,1 Paola Braghetta,7 and Alessandra Ferlini1
1Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Via Fossato di Mortara 74,
44100 Ferrara, Italy
2Department of Physical and Rehabilitation Medicine, Rizzoli-Sicily IOR, 90011 Bagheria, Italy
3Department of Neurological Sciences and Vision, Section of Clinical Neurology, University of Verona, 37129 Verona, Italy
4Department of Biology and Evolution, University of Ferrara, 44121 Ferrara, Italy
5 IGM-CNR, Unit of Bologna, c/o IOR, 40136 Bologna, Italy
6Department of Environmental and Life Sciences INSTM, University of Eastern Piedmont, 15121 Alessandria, Italy
7Department of Histology, Microbiology, and Medical Biotechnology, University of Padua, 35121 Padua, Italy
Correspondence should be addressed to Alessandra Ferlini, fla@unife.it
Received 21 March 2012; Revised 25 May 2012; Accepted 14 June 2012
Academic Editor: Steve Winder
Copyright © 2012 Elena Bassi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In Duchenne muscular dystrophy, the exon-skipping approach has obtained proof of concept in animal models, myogenic
cell cultures, and following local and systemic administration in Duchenne patients. Indeed, we have previously demonstrated
that low doses (7.5mg/Kg/week) of 2′-O-methyl-phosphorothioate antisense oligoribonucleotides (AONs) adsorbed onto ZM2
nanoparticles provoke widespread dystrophin restoration 7 days after intraperitoneal treatment in mdx mice. In this study, we
went on to test whether this dystrophin restoration was still measurable 90 days from the end of the same treatment. Interestingly,
we found that both western blot and immunohistochemical analysis (up to 7% positive fibres) were still able to detect dystrophin
protein in the skeletal muscles of ZM2-AON-treated mice at this time, and the level of exon-23 skipping could still be assessed by
RT real-time PCR (up to 10% of skipping percentage). In contrast, the protein was undetectable by western blot analysis in the
skeletal muscles of mdx mice treated with an identical dose of naked AON, and the percentage of dystrophin-positive fibres and
exon-23 skipping were reminiscent of those of untreated mdxmice. Our data therefore demonstrate the long-term residual eﬃcacy
of this systemic low-dose treatment and confirm the protective eﬀect nanoparticles exert on AON molecules.
1. Introduction
Duchenne muscular dystrophy (DMD) is an inherited X-
linked degenerative muscle disorder mainly caused by frame-
disrupting mutations following large rearrangements in the
dystrophin gene [1]. DMD boys are aﬀected by severe skeletal
muscle wasting and cardiomyopathy. However, therapeutic
approaches for this debilitating disease are now a realistic
hope.
Antisense-oligoribonucleotide (AON)-mediated exon
skipping [2–4] has indeed already entered into clinical trials
in humans. These trials are concentrating on local injection
[5, 6] and systemic administration [7, 8] of two diﬀerent
chemicals 2′-O-methyl-phosphorothioate (2′OMePS) and
phosphorodiamidate morpholino oligomer (PMO), both
administered naked. Regarding the dose regimens tested, the
local injection studies used 0.8mg of PRO051/GSK2402968
AON (2′OMePS backbone) and both/either 0.09mg and/or
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0.9mg of AVI-4658 AON (PMO backbone), inducing exon-
51 skipping in all cases [5, 6]. In phase I/II systemic clinical
trials, AVI-4658 and PRO051/GSK2402968 have been
administered by intravenous (i.v.) and subcutaneous (s.c.)
injection, using incremental doses from 0.5 to 20.0mg/Kg
and from 0.5 to 6.0mg/Kg, respectively [7, 8]. Although for
the most part studies are ongoing, they have already revealed
the absence of severe adverse eﬀects, at least at the doses
tested, and confirmed the therapeutic potential of specific
exon skipping to induce dystrophin restoration in DMD
patients.
Preclinical studies on the mdx mouse (the most fre-
quently studied animal model of dystrophy) are also under-
way, with a view to identifying the most appropriate and safe
delivery system for the AON molecules, irrespective of their
chemical formulation. The aims of these studies are to (i)
ensure more eﬃcient muscle targeting, and (ii) define the
optimal eﬀective therapeutic AON dose that will enable the
chronic life-long treatment required by DMD patients.
Rather inconveniently, the diﬀerent chemical properties
of the two AON backbones preclude the use of a universal
carrier for eﬃcient delivery. Nevertheless, recent studies have
described the use of PEG-PEI copolymers and nonionic
polymersomes as eﬃcient carriers for local delivery of
2′OMePS AONs in mdx mice [9, 10]. Furthermore, a new
formulation of PEG-PEI copolymer associated with func-
tionalized derivatives containing either the cell-penetrating
peptide TAT, adsorbed colloidal gold, or both, have also
yielded promising results [11]. Grounds for optimism have
also been provided by an approach exploiting a set of
lipid nanoparticles with diﬀerent compositions of cationic
lipids and polyethylene glycol (PEG) when tested for their
ability to deliver a luciferase siRNA to the liver via systemic
administration in mice [12, 13]. Moreover, chitosan-coated
nanoparticles have been used in mice as carriers for the in
vivo delivery of active siRNA to papillary thyroid carcinoma
by systemic administration [14]. Unfortunately, however,
activation of the complement system by conversion of C3
into C3b in serum incubated with chitosan-coated nanopar-
ticles is known to cause significant side eﬀects [15]. Hopes
are therefore pinned on a clinical trial involving the systemic
administration of siRNA using targeted nanoparticles as a
delivery system in patients with solid cancers that is currently
underway [16].
Regarding our eﬀorts in the field, we have previously
demonstrated that nonviral biocompatible nanoparticles
(NPs) (named T1 and ZM2) bind and deliver 2′OMePS
M23D AON in mdx mice by systemic intraperitoneal
(I.P.) injections. These complexes showed a body-wide
distribution and eﬃciently induced dystrophin restoration
in the skeletal muscles of the quadriceps, gastrocnemius
and diaphragm, the arrector pili smooth muscle, and the
cardiac muscle of the heart, as assessed by a routine
cohort of biochemical outcome measures (skipping quan-
tification, immunostaining, and positive fibres counting,
as well as western blotting). Our results also suggest that
these nanoparticles could aﬀord protection to antisense RNA
molecules [17, 18]. Moreover, the use of ZM2 nanoparticles
in particular has allowed us to employ very low doses of
M23D AON (7.5mg/Kg/week, 52.5mg/Kg in total), and to
observe the eﬃcacy of this systemic treatment at 1 week after
the last injection [18].
In this further study, we tested whether the protective
eﬀect of ZM2 nanoparticles on AON molecules noted was
still measurable at 3 months from the end of the same low
dosage treatment (52.5mg AON/Kg in total) and whether
the restored dystrophin protein was detectable by the same
outcome measures employed in our previous work [18].
Encouragingly, we discovered the long-term persistence
of reframed dystrophin protein expression in the skeletal
muscles of mdx mice following treatment with the same low
dosage of M23D AON, corresponding to 1/20 of the eﬀective
I.P. dosage described for naked AONs [19]. We show that
the eﬀect of ZM2–AON on dystrophin expression persists up
to 3 months (western blot positive, skipping percentage up
to 10%, and immunofluorescence positive fibres up to 7%)
from the suspension of treatment, contrasting with results
yielded by an identical naked AON dose regimen (western
blot negative, skipping percentage, and immunofluorescence
positive fibres reminiscent of untreated mdx mice).
2. Materials and Methods
2.1. Animals. All experiments were performed on male mdx
mice (C57BL/10ScSn–Dmdmdx/J) and age-matched wild-
type (WT) male mice (C57BL/10SnJ). All procedures were
approved by the Animal Experimentation Ethics Committee.
Mice were purchased from the Jackson Laboratory (Bar
Harbor, ME) and housed in temperature-controlled rooms
(22◦C) at a humidity level of 50% and a 12 : 12 hour light–
dark cycle.
2.2. ZM2-M23D AON-Loading Experiments. ZM2s are
cationic core-shell nanoparticles made up of a PMMA core
surrounded by a random copolymer shell consisting of
units derived from N-isopropyl acrylamide+ (NIPAM) and
reactive methacrylate-bearing cationic groups [18]. M23D
AON, which contains a 2′-O-methyl RNA phosphoroth-
ioate backbone, was synthesized as previously described
[17]. Loading experiments showed that ZM2 nanoparticles
(1mg/mL) adsorbed 2′OMePS M23D oligoribonucleotide
onto their surface in the concentration range 10–100 μg/mL.
M23D adsorption onto ZM2 nanoparticles is a highly
reproducible process with a loading value of 90 μg/mg [18].
2.3. I.P. Injections of ZM2-M23D AON Complexes or Naked
M23D AON in mdx Mice. Mdx male mice (6 weeks of age)
were I.P. injected with either 200 μL of ZM2-M23D complex
containing 225 μg of M23D AON and 2.5mg of ZM2
nanoparticles dissolved in sterile, unpreserved saline solution
(0.9% sodium chloride), or 200 μL containing 225 μg of
M23D dissolved in unpreserved saline solution (naked AON)
and monitored according to approved NIH and University
guidelines. A summary of the injection schedule is shown
in Table 1. Four additional mdx mice were injected with
200 μL containing 2.5mg of ZM2 NPs dissolved in sterile
unpreserved saline solution (0.9% sodium chloride). The
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total amount of M23D AON received by each animal was
7.5mg/Kg/week, 52.5mg/Kg in total. One group of mdx
mice (n = 4) received seven injections of ZM2-M23D
complex once a week for seven weeks, the second group
(n = 4) received seven injections of M23D–naked AON, and
the third (n = 4) received seven injections of ZM2 NPs at
the same times. Four noninjected (not treated) age-matched
mdx mice were used as controls.
2.4. RNA Studies. Total RNA was extracted from frozen
sections of muscle biopsies using TRIzol (Invitrogen, Milan,
Italy), and reverse-transcribed into cDNA using the High-
Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems, Frankfurt, Germany).
Exon-specific real time assays (ESRAs) [20] were used on
exons 8, 23, and 25 to quantify the percentage of exon-23
skipping in treated, with respect to untreated mice (ΔΔCt
method), using β-actin as endogenous control, as previously
described [17].
2.5. Immunofluorescence Analysis. At 12 weeks after the last
injection, all mdx mice were killed, and their diaphragm,
quadriceps and cardiac muscles isolated, blotted dry,
trimmed of external tendon, snap-frozen in liquid N2-cooled
isopentane, and stored at −80◦C until further processing.
Seven-micrometer-thick frozen transverse sections were cut
from at least two-thirds of the length of the heart, diaphragm
and quadriceps muscles, and for each muscle at least 5 slices
were cut at 150 μm intervals.
To analyse dystrophin restoration, freshly cut muscle sec-
tions were labelled with a polyclonal antidystrophin antibody
(H-300, diluted 1 : 100; Santa Cruz Biotechnology, Santa
Cruz, CA) and revealed with anti-rabbit Cy3-conjugated sec-
ondary antibody (Jackson Immunoresearch, Suﬀolk, UK).
For the semiquantitative analysis of dystrophin, all samples
were double-labelled with a rat monoclonal antibody for
laminin-2 (a2-chain, 4H8-2, diluted 1 : 500; Alexis Biochem-
ical, Farmingdale, NY, USA), followed by anti-rat Cy2-
conjugated secondary antibody (Jackson Immunoresearch,
Suﬀolk, UK). The percentage of fibres with a dystrophin
labelling that covers at least 80% of the sarcolemma perime-
ter was then calculated in treated (ZM2-AON and naked
AON) compared to untreated (NT) mdx mice [17]. At least
1000 muscle fibres obtained from five diﬀerent levels of
tissue blocks for each sample were studied for statistical
evaluation. All images were observed with a Nikon Eclipse
80i fluorescence microscope (Nikon Instruments, Florence,
Italy) connected to at a high-resolution CCD camera (Nikon
Instruments, Florence, Italy) at 20x magnification. For
statistical analysis, all the data were analysed by means of
Student’s t-test.
2.6. Tissue Morphology Analysis. Sections obtained from
several blocks of kidney of mdxmice treated with ZM2-AON
and untreated mdx (control) were stained with hematoxylin
and eosin (H&E) (Sigma-Aldrich, Milan, Italy) and anti-
collagen I antibody (diluted 1 : 80, Abcam, Cambridge, UK),
and observed at 10x and 20x with a Nikon Eclipse 80i
microscope. Images were recorded with a Nikon digital
camera.
2.7. Western Blot Analysis. Western blot analysis was per-
formed as previously described [17]. Briefly, twenty-
micrometer-thick frozen muscle sections were homogenized
with a lysis buﬀer (7mol/L urea, 2mol/L thiourea, 1%
amidosulfobetaine-14, and 0.3% dithioerythritol). Aliquots
of proteins fromwild typemice (15 μg) and from themuscles
of treated or untreated mdx mice (150 μg) were loaded
onto a 6% sodium dodecyl sulphate–polyacrylamide gel and
separated by electrophoresis. Samples were transferred to a
nitrocellulose membrane at 75V, and the membrane was
incubated overnight at 4◦C with the specific antibody DYS2
(NovoCastra, Newcastle, UK). To quantify the restoration
of dystrophin protein in treated versus wild-type mice,
a densitometric analysis of autoradiographic bands was
performed with a Bio-Rad Densitometer GS 700 (Bio-Rad,
Milan, Italy), followed by normalization with the quantity of
total protein loaded onto the gels.
3. Results
3.1. I.P. Injections of ZM2–AON Complexes and Naked AON
in mdx Mice. 12 mdx male mice were treated (from 6 weeks
of age) via intraperitoneal injections once a week for 7 weeks:
4 mice received the ZM2–AON complex (7.5mg/Kg/week
of AON), 4 mice received naked AON (7.5mg/Kg/week of
AON), and 4 mice received the ZM2 NPs. Controls were 4
age-matched mdx mice that did not receive any treatment.
All animals were sacrificed 12 weeks after the last injection
(at 6 months of age). Table 1 summarizes the treatment and
sacrifice of the mice analysed in the present study.
Intraperitoneal injection was adopted as the best admin-
istration route after preliminary studies showed that i.v.
injections of nanoparticles via caudal vein induced venous
lesions and subsequent necrotic areas in the tail in a
significant number of mice, probably due to obstructing
nanoparticle aggregates; furthermore, subcutaneous injec-
tion resulted in local accumulation with no circulation of
nanoparticles and no AON release (Ferlini A. and Rimessi
P., unpublished observations).
3.2. Dystrophin RNA Analysis: Evaluation of Exon-23 Skipping
in mdx Mice. In order to test the eﬃcacy of the two
treatments, we conducted three diﬀerent experiments to
assess exon-23 skipping levels, using a Real-Time PCR exon-
specific assay (ESRA) of our own devising as previously
reported [17, 21]. Skipping percentages were calculated in
treated with respect to untreated mice.
Figure 1 summarizes the results obtained in the quadri-
ceps, diaphragm and heart. Small percentages of exon-23
skipping were detected in all muscles from ZM2–AON- and
naked AON-treated mice: 9.5% in the diaphragm, 7.8% in
cardiac muscle and 6.3% in the quadriceps of mice receiving
ZM2-AON treatment, and 6.5% in the diaphragm, 3.3% in
cardiac muscle and 2.6% in the quadriceps of those treated
with naked AON. Only in the diaphragm and quadriceps
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Table 1: Injection schedule.
Group (n◦ of mice) Formulations N◦ of I.P. injections (1/week) Sacrifice
Naked AON (n = 4)
M23D-AON
225 μg/injection
(7.5mg/Kg/week)
7 12 weeks after last injection
ZM2-AON (n = 4)
ZM2 2.5mg
M23D-AON
225 μg/injection
(7.5mg/Kg/week)
7 12 weeks after last injection
ZM2 (n = 4) ZM2 2.5mg/injection 7 12 weeks after last injection
Not Treated (n = 4) Not Treated Not Treated 12 weeks after last injection
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Figure 1: RT real time PCR exon-skipping quantification. His-
tograms show the percentages of exon–23-skipped transcript,
calibrated on exons 8 and 25 (ΔΔCt method) and calculated in
treated (ZM2-AON and naked AON) with respect to untreatedmdx
mice. The in-frame skipped product was detected in all skeletal
muscles and the heart at percentages ranging from 6.3 to 9.5%
in ZM2–AON-treated mice (black bars) and from 2.6 to 6.5%
after treatment with naked AON (grey bars). Asterisks (∗) indicate
statistical significance at P < 0.005. Error bars represent mean± SD.
were the diﬀerences between the treatment with or without
ZM2 nanoparticles statistically significant. In fact, in the
cardiac muscle from naked AON- and ZM2–AON-treated
mdx mice, the values of exon-23 skipping (ranging from
3.3% to 7.8%) were similar to the physiological skipping
present in untreated mdx mice (Figure 1). In muscles
from mice receiving ZM2 uncomplexed NP, the skipping
percentages were similar to those measured in untreatedmdx
mice (data not shown).
3.3. Immunofluorescence Analysis. In order to quantify
dystrophin-positive fibres and to evaluate the correct local-
ization of dystrophin, wild-type, treated and untreated
mdx muscle sections were double-labelled with anti-laminin
alpha2-chain antibody, as a marker of muscle fibre basement
membrane reported to be unaﬀected in dystrophin deficient
muscle [22], and with a polyclonal antidystrophin antibody.
As shown in Figure 2(a), immunofluorescence analysis
revealed the presence of dystrophin three months after
the end of treatment in the quadriceps and diaphragm of
both naked AON and ZM2-AON-treated mice. Dystrophin
was correctly localized at the plasma membrane of muscle
fibres, as confirmed by double-labelling with anti-laminin
alpha2 chain antibody (not shown). Although the labelling
pattern was discontinuous in most of fibres from both ZM2–
AON- and naked AON-treated mice, groups of fibres with
continuous dystrophin labelling (greater than 80% of the
fibre’s perimeter) could be detected in ZM2–AON-treated
samples only (Figures 2(a) and 2(b)). Semiquantitative anal-
ysis of fibres with continuous dystrophin labelling showed
a significantly higher percentage after treatment with ZM2-
AON (7.2% in the quadriceps and 4.5% in the diaphragm)
with respect to naked AON (1.6% in the quadriceps and 0.2%
in the diaphragm), which yielded levels reminiscent of the
untreated mdx mice used as control (Figure 3). The heart
resulted negative (Figure 3).
Immunofluorescence analysis performed on muscles
from ZM2 uncomplexed NP-treated mice revealed a number
of dystrophin positive fibres similar to that found in control
untreated mdx mice (data not shown).
3.4. Tissue Morphology Analysis. Tissue morphology analysis
of mdx mice treated with ZM2-AON versus untreated mdx
(control) showed no apparent tissue damage, an absence
of morphological alterations, no cell architecture modifi-
cations, and an absence of inflammatory infiltrates in the
kidney in either group (Figure 4).
3.5. Western Blotting. Western blot analysis, performed as
previously described [17], confirmed the presence of high-
molecular-weight dystrophin protein only in the quadriceps
and diaphragms of ZM2–AON-treated mdx mice (Figure 5).
Interestingly, no protein was detected in the muscles from
mice treated with naked AON.
4. Discussion
These findings demonstrate the persistence of dystrophin
protein in mdx mice systemically treated with 2′OMePS
AON adsorbed onto ZM2 nanoparticles, 3 months after the
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Figure 2: Immunofluorescence analysis. (a) Restored dystrophin is detectable and correctly expressed at the membrane of muscle fibres
(quadriceps and diaphragm) from ZM2–AON-treated mdx mice. Traces are also visible in skeletal muscles from naked AON-treated mice,
although the distribution at the sarcolemma is not continuous and very faint. Cardiac muscles were found to be negative for restored
dystrophin. (Scale bar = 100 μm in quadriceps, 50 μm in diaphragms, 25 μm in heart). (b) Here are represented some enlarged details
of immunofluorescence images that highlight the diﬀerent expression patterns of rescued dystrophin in the quadriceps and diaphragm of
ZM2–AON- and naked AON-treated mdxmice. These images show both a brighter dystrophin labelling and a more continuous distribution
along the fibre membranes in muscles from ZM2–AON-treated mice (NT, untreated; WT, wild type).
interruption of the treatment. At this juncture, restored dys-
trophin protein was still visible under immunofluorescence
analysis, and shown to be correctly localized at the muscle
fibre sarcolemma in the diaphragm, near to the injection
site, and in the quadriceps, a distal muscle. The count of
dystrophin positive fibres with continuous labelling shows
a low level of positivity, although significantly higher with
respect to that observed in naked AON-treatedmice.Western
blotting confirmed the correct molecular weight of this
almost full-length protein. This result is very encouraging
considering that the low-dose treatment was suspended 3
months before the sacrifice.
To put these findings into context, although immunoflu-
orescence analysis in naked AON-treated mice did show
dystrophin-labelling in the skeletal muscles both proximal
(diaphragm) and distal (quadriceps) to the site of I.P.
injection, the restored protein was found to be localized
irregularly at the sarcolemma (patchy). Interestingly, how-
ever, no restored protein was detected by western blot,
a technique that reflects the total amount of dystrophin
protein translated and present in the cells, in contrast to
immunofluorescence, which mirrors only the dystrophin
anchored at the sarcolemma [5].
When approaching skeletal muscles diseases with molec-
ular therapies, it has to be considered that muscles are mult-
inucleated syncytia and the rescue of a single-muscle fibre
requires correction of multiple nuclei. In dystrophinopathy,
each reverted single nucleus determines dystrophin expres-
sion in a restricted region of the fibre comprised within its
nuclear domain [23]. Hence, the lower percentages of fibres
with a continuous labelling pattern (>80% of the perimeter)
in mice treated with naked AON with respect to those
treated with ZM2-AON could derive from a lower fraction
of corrected nuclei. Although it is diﬃcult to establish the
minimal number of nuclei, it seems reasonable to suggest
that a large number of nuclei have to be corrected to
ensure the persistence of detectable levels of dystrophin
expression [23], a theory that would explain the absence
of dystrophin protein in western blot from naked AON-
treated muscles. Neither treatment (naked AON or ZM2-
AON) appeared to restore dystrophin protein in the heart, an
unsurprising finding considering that cardiac muscle is the
6 Journal of Biomedicine and Biotechnology
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Figure 3: Dystrophin-positive fibre counting. Dystrophin-positive
fibre counting was performed on fibres with a labelling that covers
at least 80% of the sarcolemma perimeter. Images were recorded and
processed using identical exposure parameters. The graph shows the
percentage of dystrophin-positive fibres detected in the muscles and
heart from ZM2–AON- (black columns) and naked AON-treated
(grey columns) mdx mice, calculated with respect to untreated
mice, on sections representative of the total muscle. Quadriceps and
diaphragm from ZM2–AON-treated mice show significantly higher
percentages of dystrophin-positive fibres (7.2% in quadriceps and
4.5% in diaphragm) than the same muscles from mice treated
with naked AON (reminiscent of untreated mdx mice). Negligible
levels of dystrophin-positive fibres were detected in the heart of
both treatment groups. Percentages of positive fibres in muscles
from treated mice (ZM2-AON and naked AON) were calculated by
subtracting the percentages detected in untreated mdx mice (up to
3%), considered as baseline (% positive fibres in treated mice−%
positive fibres in untreated mice). The significance was calculated
with respect to naked AON-treated mice (error bars represent mean
± S.E.M., n = 10, t-test, and ∗P < 0.05, ∗∗P < 0.001).
more diﬃcult disease target to be reached, at least when using
ineﬃcient delivery systems or low doses of AONs [19, 24, 25].
Indeed the use of peptide-conjugated PMO molecules, in
particular CPP-PMO and Pip5e-PMO, have been shown as
very eﬃcient at dealing with dystrophin restoration in the
heart, due to the presence of stretches of arginines and a
central hydrophobic core, which enhanced nuclear PMO
delivery in cardiomyocytes [26–28].
5. Conclusions
In conclusion, this is the first study on phosphorothioate
oligoribonucleotides, both naked and loaded onto NPs,
documenting a long-lasting eﬀect at such a low dose
(7.5mg/Kg/week, 52.5mg AON/Kg in total). Indeed, this
corresponds to 1/20 of the doses used for the mdx mouse
in previous systemic studies [19, 29].
At this point in time, although encouraging enough to
warrant clinical trials, the results obtained in mice with
naked 2′OMePS AON seem to indicate that the doses
required for a therapeutic eﬀect might be too high for long-
term treatment in humans. In fact, systemic naked AON
(a) (b)
(c) (d)
Mdx control
(e)
Mdx-ZM2-AON treated
(f)
Figure 4: Tissue morphology analysis. Histological analysis on
kidneys from control and ZM2-AON-treated mdx mice. (a) and
(b) Hematoxylin and Eosin staining; (c–f) immunohistochemistry
with anticollagen I antibody; (a–d) 10x; (e) and (f): 20x. No
morphological alterations were observed in either group of mice.
delivery in animal models only yielded satisfactory levels of
dystrophin rescue in both skeletal and cardiac muscles at
amounts of AON ranging from 300mg/Kg to 1250mg/Kg
[19, 30]. Nevertheless, better results have been reached
with more moderate doses of PMO AONs, that is, roughly
600mg/Kg [31].
Until now, the long-term persistence of restored dys-
trophin protein after low-dosage systemic treatment has
only been achieved using naked morpholino or, more
promisingly, molecules conjugated with a cell-penetrating
peptide (CPP) containing a stretch of arginines [19, 32–34].
All these diﬀerent AON formulations still raise safety
implications, regarding their nondegradable nature (PMO,
[9]), their possible toxicity (PPMO, [35]) and the renal
overload (2′OMePS, [19, 36, 37]). This is especially true for
long-life treatments as those required for DMD.
In this paper, we reemphasize our previous results
regarding the use of ZM2 nanoparticles as a nontoxic
vehicle for RNA molecules [18], and we show that the
protective eﬀect of the ZM2 remains at 3 months from the
interruption of treatment. In fact, the dystrophin restoration
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Figure 5: Western blot analysis. Immunoblotting for dystrophin
using DYS2 antibody showed restored expression of the protein in
the quadriceps and diaphragm of ZM2–AON-treated mice (lane
4), while no protein was detected in either untreated control (NT,
lane 2) or naked AON-treated mdx mice (lane 3). Dystrophin
protein was undetectable in the hearts of both untreated and
treated mdx mice. Quadriceps, diaphragms, and hearts from WT
mice were used as positive controls (lane 1). For WT samples,
the total protein loaded was 1/10 (15 μg) of the quantity in the
other lanes (150 μg). Quantification performed by densitometric
analysis of autoradiographic bands followed by normalization
with the quantity of total protein loaded onto the gel showed a
dystrophin recovery of 8 ± 0.6% in quadriceps and 7 ± 0.17%
in diaphragm (P = 0.0002) of ZM2–AON-treated mice with
respect to WT control mice. The results are representative of three
separate experiments. Data are given as means ± S.E.M. and the
statistical significance has been calculated with the Student’s t-test
for unpaired data.
and exon-23 skipping are still measurable in skeletal muscles
(quadriceps and diaphragms) of ZM2-AON treated mdx
mice, as highlighted by immunofluorescence, western blot
and ESRA analysis.
Previous works on the mdx mouse have suggested that
levels of 30% of dystrophin or more are protective for
mice [38, 39], and Neri et al. demonstrated that dystrophin
mRNA and protein levels between 29% and 57% of control
muscle are suﬃcient to avert muscular dystrophy in humans,
when the protein is uniformly present in all muscle fibres
[40]. Though we are well aware that the rescue percentages
detected in our experiments are much lower, we do believe
that these results could be a starting point for the optimiza-
tion of a treatment featuring ZM2-AON complexes. In the
future, we will work to clarify both the kinetic and dynamic
process underlying NP-AON treatments by studying the
biodistribution/clearance of ZM2-AON complexes and opti-
mizing their dose regimen. Work will also be necessary
to fine-tune their kinetics and devise novel formulations,
taking advantage of the intrinsic physical plasticity of ZM2
nanoparticles. Indeed the protective eﬀect exerted by NPs on
AONs, which undoubtedly plays a role in persistence of the
protein by means of prolonging the beneficial eﬀect of AON
treatment certainly encourages the exploration of innovative
administration routes of this compound.
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